Immutep Ltd and Merck Announce Second Clinical Trial Collaboration
Immutep (IMMP) develops novel immunotherapy treatments for cancer, infectious disease and autoimmune diseases.
Today, Immutep announced a second clinical trial collaboration and supply agreement with Merck & Co (MRK) subsidiaries, Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada).
Immutep will conduct a new Phase IIb clinical trial in 1st line head and neck squamous cell carcinoma (HNSCC) patients.
The trial, called TACTI-003 (Two Active Immunotherapies), will be a 1:1 randomized, controlled clinical study in approximately 160 first-line HNSCC patients.
The trial will evaluate the safety and efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti or IMP321) in combination with Merck’s immunotherapy product KEYTRUDA® (pembrolizumab), compared to pembrolizumab alone.